Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

Journal of Clinical Psychopharmacology
Elias AboujaoudeNona Gamel

Abstract

Data from the fields of genetics, neuroimaging, and animal studies, along with case reports and small clinical trials, point to a role for glutamatergic dysfunction in the pathophysiology of obsessive-compulsive disorder (OCD). We report on the first open-label study to test the hypothesis that memantine, a noncompetitive glutamate antagonist, will result in a clinically meaningful reduction in OCD symptoms in adults with treatment-resistant OCD. We recruited 15 adult subjects with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-defined OCD and a baseline Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) of 18 or higher, who had failed to respond to treatment with a serotonin reuptake inhibitor (SRI), given at an adequate and stable dose for at least 12 weeks. The duration of memantine treatment was 12 weeks, and the dose was gradually increased to a target of 20 mg/d. Response was defined as a 25% or greater reduction in the Y-BOCS score at study end and a Clinical Global Impression-Improvement scale rating of "much" or "very much" improved. Data from 14 subjects were analyzable. Mean baseline Y-BOCS score was 27.4 (SD, 5.0). Subjects had failed an average of 2.8 (SD, 1.8) SRI trials; 6 subjects had failed a...Continue Reading

Associated Clinical Trials

Dec 12, 2005·John J Barry, John J Barry

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Nov 1, 1989·Archives of General Psychiatry·W K GoodmanD S Charney
Nov 1, 1989·Archives of General Psychiatry·W K GoodmanD S Charney
Jun 17, 1998·Journal of the American Academy of Child and Adolescent Psychiatry·G J MooreD R Rosenberg
Sep 15, 2000·Journal of the American Academy of Child and Adolescent Psychiatry·D R RosenbergG J Moore
Jul 24, 2001·The International Journal of Neuropsychopharmacology·D R RosenbergG J Moore
Aug 15, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·J BoltonD R Rosenberg
Jul 15, 2003·Neurosurgery Clinics of North America·Benjamin D GreenbergSteven A Rasmussen
Sep 29, 2004·The International Journal of Neuropsychopharmacology·Naomi A Fineberg, Tim M Gale
Apr 21, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kaushik ChakrabartySumant Khanna
Jul 5, 2005·Biological Psychiatry·Vladimir CoricJohn H Krystal
Nov 3, 2005·The American Journal of Psychiatry·Michael PoyurovskyLorrin Koran
Nov 3, 2005·The American Journal of Psychiatry·Spiridon PapapetropoulosCarlos Singer
Jan 6, 2006·Methods and Findings in Experimental and Clinical Pharmacology·K ShinomiyaC Kamei
May 4, 2006·The Journal of Clinical Psychiatry·Bernardo Dell'OssoEric Hollander
May 30, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Massimo Pasquini, Massimo Biondi
Jul 5, 2006·Archives of General Psychiatry·Paul Daniel ArnoldJames L Kennedy
Nov 6, 2007·Neurotoxicology·C ChipanaE Escubedo
Mar 5, 2008·Journal of Child and Adolescent Psychopharmacology·Paul GrantSusan E Swedo
Mar 19, 2008·Expert Review of Neurotherapeutics·Joseph Zohar
Apr 22, 2008·European Journal of Pharmacology·Nobuaki EgashiraMichihiro Fujiwara

❮ Previous
Next ❯

Citations

Feb 8, 2011·Journal of Neural Transmission·Ewa PoleszakPiotr Wlaź
Jun 21, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Carolyn I RodriguezHelen B Simpson
Nov 26, 2010·Cognitive Behaviour Therapy·Lisa D VaccaroBethany M Wootton
Aug 10, 2010·Behavioural Pharmacology·Plinio C CasarottoFrancisco S Guimarães
Nov 26, 2013·Current Opinion in Psychiatry·Catherine Kariuki-NyutheDan J Stein
Oct 31, 2012·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Alline Cristina CamposFrancisco Silveira Guimarães
Feb 27, 2013·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Dennis L MurphyKiara R Timpano
Sep 21, 2011·Neuropsychiatric Disease and Treatment·Kelda H Walsh, Christopher J McDougle
Oct 7, 2010·The Journal of Clinical Psychiatry·Carolyn I RodriguezHelen Blair Simpson
Sep 1, 2012·Case Reports in Psychiatry·Thomas L SchwartzShafi Raza
Jul 12, 2014·Industrial Psychiatry Journal·Ajay Kumar BakhlaSuprakash Chaudhury
Aug 12, 2014·Health Technology Assessment : HTA·Samantha BartonSteven J Edwards
Jan 1, 2014·Expert Opinion on Emerging Drugs·Stefano PallantiAndrea Cantisani
Oct 24, 2013·Expert Opinion on Drug Discovery·Marco A GradosDiandra Fortune
May 31, 2013·Expert Opinion on Investigational Drugs·Joanna M Wierońska, Andrzej Pilc
Aug 11, 2015·Journal of Child and Adolescent Psychopharmacology·Scott R Pekrul, Kate D Fitzgerald
Jan 10, 2012·The International Journal of Neuropsychopharmacology·Naomi A FinebergIlenia Pampaloni
Sep 10, 2014·Frontiers in Pediatrics·Daniel A Rossignol, Richard E Frye
May 17, 2011·Pharmacology, Biochemistry, and Behavior·Carlos Riaza Bermudo-SorianoEnrique Baca-Garcia
Sep 20, 2011·Neuroscience·N Albelda, D Joel
Nov 6, 2012·The Australian and New Zealand Journal of Psychiatry·Naomi A FinebergIlenia Pampaloni
Jun 25, 2015·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·David CastleSusan Rossell
Jul 25, 2017·ACS Chemical Neuroscience·Shahrina AlamCraig W Lindsley
Sep 17, 2013·Human Psychopharmacology·Harpal Singh NandhraAkeem Sule
Jun 15, 2016·Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie·Timo D VloetMichael Simons
Oct 16, 2018·Expert Opinion on Pharmacotherapy·Giacomo Grassi, Stefano Pallanti
Apr 22, 2011·Journal of Clinical Psychopharmacology·Po-Lun WuGuochuan E Tsai
Sep 2, 2011·Journal of Clinical Psychopharmacology·Erica B BernhardtChristopher J McDougle
Jan 16, 2010·Journal of Clinical Psychopharmacology·Massimo PasquiniMassimo Biondi
Nov 10, 2017·Current Medicinal Chemistry·Donatella MarazzitiArmando Piccinni
May 30, 2017·Current Medicinal Chemistry·Lorrin M Koran, Elias Aboujaoude
Apr 23, 2013·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·S E StewartC A Mathews
Nov 28, 2013·Annals of the New York Academy of Sciences·Amy RappMoira Rynn
May 1, 2019·Expert Opinion on Pharmacotherapy·Nancy DongEric Hollander
Feb 2, 2013·Expert Review of Neurotherapeutics·Shyam Sundar Arumugham, Janardhan Y C Reddy
May 6, 2020·Neuropsychiatric Disease and Treatment·Sheshachala KarthikJanardhanan C Narayanaswamy
Jan 13, 2011·Depression and Anxiety·Moira RynnHilary Vidair
Jan 1, 2013·Trends in psychiatry and psychotherapy·Adelar Pedro FranzYgor Arzeno Ferrão

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Kaushik ChakrabartySumant Khanna
Progress in Neuro-psychopharmacology & Biological Psychiatry
Massimo Pasquini, Massimo Biondi
© 2021 Meta ULC. All rights reserved